Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal

Abstract

The many advantages of registered bioidentical sex hormones over registered, conventional, non-bioidentical menopausal hormone therapy (MHT) are considered. The transdermal route of estrogen administration avoids excess venous thromboembolic and ischemic stroke events. There is some indication that conjugated equine estrogens are more thrombogenic and most likely induce some hypertensive responses; estradiol might also be superior to conjugated equine estrogens (CEE) in terms of global cardiovascular health. The most valid evidence presently suggests that CEE-only treatment does not increase the risk of breast cancer and even may reduce it. But its combination with a synthetic progestogen (mainly medroxyprogesterone acetate) is a critical issue since it seems to be primarily associated with an increased incidence of breast cancer, however similar to or lower than that associated with some common lifestyle factors. Though not yet proven in a randomized, controlled trial, MHT continuously combining oral micronized progesterone with transdermal estradiol can presently be considered as the optimal MHT. It is not only safer than custom-compounded bioidentical hormones but also than oral conventional MHT and has the best breast profile; registered products for such optimal MHT are available around the world and must be preferred.

Keywords:

• Menopausal hormone therapy
• registered bioidentical hormones
• transdermal estradiol
• natural progesterone
• breast cancer
• thromboembolic events
• cardiovascular events and mortality
• ischemic stroke

Conflict of interest

Lately M. L’H. has occasionally received consultancy honoraria and/or lecture fees from Besins Health Care International, TEVA and Merck/MSD.

Source of funding

Nil.